Articles On Orthocell (ASX:OCC)

Race Oncology says bisantrene + decitabine effective Race Oncology (ASX:RAC) jumped 8% this morning after sharing the results from recent preclinical studies conducted at Oncolines B.V. in the Netherlands. In these studies, bisantrene (Race...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX200 closed around a quarter of a per cent up with Consumer discretionary topping the gains, finishing nearly half a per cent up and Utilities and Industrials both losing around half a per cent. In the green Mineral explorer IGO...

Regenerative medicine company Orthocell (ASX:OCC) has published encouraging findings from its Remplir nerve regeneration clinical trial, unveiling promising progress in its peripheral nerve repair journey – offering hope for millions of peo...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Perth clinical dermatology company Botanix has been elevated into the All Ordinaries index made up of the top 500 companies listed on the Australian Securities Exchange.

Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.

Regenerative medicine company Orthocell says it has successfully completed the first stage of a pivotal US market authorisation study for its nerve repair product, paving the way for global expansion.

Argenica granted US FDA’s Rare Pediatric Disease Designation Orthocell completes Remplir study, targets US$1b+ nerve repair device market LTR Pharma progresses Erectile Dysfunction study   Argenica gets FDA approval Argenica Therapeutics...

Biotech tends to follow a four to five year market cycle and those in the sector say there are signals that the next upturn has begun. That was the message today as four biotech companies and Life Sciences WA presented to 200 brokers and...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

The $3.5m of shares have been taken up by prominent investors Chris Ellison, Rod Jones, Malcolm and Tonya McCusker and Michael Malone, along with the Merchant Biotech Fund.

  Local markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat   The ASX200 has ended a second slumbrous session slightly lower, with a little dribble in the shape of the Star Casino at the corner of its mouth. US M...

Orthocell (ASX:OCC) has announced the final results from its clinical study comparing OrthoATI to surgery to treat severe, chronic, treatment-resistant lateral epicondylitis.

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

In drug development there’s a narrow window to get to market and long delays tend to be fatal – and not just for the patients. Ten years ago, Pharmaxis was confident of US Food and Drug Administration approval for its cystic fibrosis treatm...

Perth-based regenerative medicine company Orthocell has appointed famed plastic surgeon Fiona Wood to its board as a non-executive director.

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Orthocell’s sales ramped up in three months to June with the Perth-based regenerative medicine company described as testament to the quality of its products and distribution partners.

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Australian regenerative medicine company Orthocell (ASX:OCC) has appointed John Van Der Wielen as independent non-executive chairman.

Orthocell has launched a new bio-manufacturing facility in what boss Paul Anderson said represented the successful translation of quality science into a world-class product.

Pfizer said its diabetes drug works as well as Ozempic for weight loss What are the side effects of these weight loss drugs? Best and worst performing ASX biotechs over the past week   Earlier this week, Pfizer surprised the market by say...

The Federal Budget delivers billions of dollars funding into healthcare and aged care Mental health and Telehealth also received significant funding allocations Here are the ASX stocks that could benefit   Medicare, telehealth and mental...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The Australian share market dipped on Tuesday, with the benchmark ASX 200 index down nearly 20 points halfway through the trading day. The materials sector led the pack in early trade — the only sector to edge into the green. Critical...

Neuren’s breakthrough drug DAYBUE starts selling in the US Orthocell commences nerve repair study   Market darling Neuren Pharma (ASX:NEU) jumped 4% today after announcing that DAYBUE (trofinetide) is now officially available for the trea...

Orthocell (OCC) kicks off a ‘comparator’ study as part of its pre-clinical and clinical development program in nerve repair and regeneration OCC will use a rat sciatic nerve injury model to evaluate the safety, mechanism of action and pr...

Labor has announced that if elected it will launch a $38 million expansion of Australia's newborn screening programs in a move that will effectively see the national take over the current 'postcode lottery' for babies.

Orthocell (OCC) appoints internationally-recognised nerve surgeons Professor Christopher Dy and Professor David Brogan to its medical scientific advisory board The company says the appointments will assist with clinical development and U...

Telehealth specialist Global Health signs partnership deal with Woolworths subsidiary The deal will see Global Health provide virtual access to healthcare practitioners Orthocell hires experts to drive US market entry   Telehealth special...

Orthocell says a $23 million manufacturing deal for its product has put the regenerative medicine company on the radar of global industry heavyweights, paving the way for other WA firms to do the same.

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Surgeons can now be reimbursed for the use of Orthocell’s nerve-reconstruction device SaaS player ReadyTech is considering a takeover offer from an Aussie private equity firm Creso is raising up to $7.6m to advance sales and marketing of i...

Orthocell’s (OCC) Remplir product is included on the Australian Prostheses ListThe company says inclusion in the list enables surgeons to receive reimbursement from private insurers for the use of Remplir in peripheral nerve repair procedur...

Regenerative medicine company Orthocell (ASX:OCC) has announced that its Remplir has been added to the federal government's Prostheses List.

We take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks from 2021 have gained since listing We also look at the best and worst performing ASX stocks over the past month   There were 191 ASX IPOs in...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

ShareCafeRebound rally: Aus shares close 1.4 per cent higher by Lauren Hayes   The S&P/ASX 200 enjoyed a rebound today, with the market up 2 per cent in intraday trading, closing 1.44 per cent or 93 points higher at 6555.00. All 11 sect...